FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Staib

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Anatomy

Bone Marrow

Co-author Network

Publications

TOP 3
Carmen Schweighofer; Sabine Sperka; Peter Staib; Sandra Stein; Armin Tuchscherer; Semra Ismail; Thorsten Meyer; Benno Rattel; Marcel Reiser; Thomas Elter; Michael Hallek
Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study.
Thomas Elter; Andreas Engert; A-M Fink; K Fischer; W Gassmann; J Bahlo; Sebastian Böttcher; Andreas Bühler; R Busch; Hartmut Döhner; I Hasan; R James; C Kahl; Matthias Ritgen; Peter Staib; M Stauch; Stephan Stilgenbauer; Clemens-Martin Wendtner; Dirk Winkler; Michael Hallek
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
Kirsten Fischer; Valentin Goede; Michael Hallek; Susanne Isfort; Michael Kneba; Karl-Anton Kreuzer; Karl H Pflüger; Matthias Ritgen; Silke Schott; Jöerg Schubert; Peter Staib; Stephan Stilgenbauer; Julia von Tresckow; Jasmin Bahlo; Sebastian Böttcher; Andreas Bühler; Raymonde Busch; Paula Cramer; Hartmut Döhner; Barbara F Eichhorst; Anna-Maria Fink; Dirk Winkler; Clemens-Martin Wendtner
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Staib (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Carmen Schweighofer; Sabine Sperka; Peter Staib; Sandra Stein; Armin Tuchscherer; Semra Ismail; Thorsten Meyer; Benno Rattel; Marcel Reiser; Thomas Elter; Michael Hallek
Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study.
Cancer immunology, immunotherapy : CII 2012;61(12):2367-73.
2012: Thomas Elter; Andreas Engert; A-M Fink; K Fischer; W Gassmann; J Bahlo; Sebastian Böttcher; Andreas Bühler; R Busch; Hartmut Döhner; I Hasan; R James; C Kahl; Matthias Ritgen; Peter Staib; M Stauch; Stephan Stilgenbauer; Clemens-Martin Wendtner; Dirk Winkler; Michael Hallek
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
Leukemia 2012;26(12):2549-52.
2012: Kirsten Fischer; Valentin Goede; Michael Hallek; Susanne Isfort; Michael Kneba; Karl-Anton Kreuzer; Karl H Pflüger; Matthias Ritgen; Silke Schott; Jöerg Schubert; Peter Staib; Stephan Stilgenbauer; Julia von Tresckow; Jasmin Bahlo; Sebastian Böttcher; Andreas Bühler; Raymonde Busch; Paula Cramer; Hartmut Döhner; Barbara F Eichhorst; Anna-Maria Fink; Dirk Winkler; Clemens-Martin Wendtner
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(26):3209-16.
2011: Maria J G T Vehreschild; Marie von Lilienfeld-Toal; Mohammed Wattad; Hildegard Christ; Oliver Andreas Cornely; Martin Hellmich; Meinholf Karthaus; Georg Maschmeyer; Arne M K Meissner; Silke Neumann; Peter Staib; Jörg Vehreschild
Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients.
Haematologica 2011;96(12):1855-60.
2011: Kirsten Fischer; Valentin Goede; Michael Hallek; Michael Kiehl; Michael Kneba; Gabriele Kranz; Carmen Schweighofer; Peter Staib; Stephan Stilgenbauer; Jasmin Bahlo; Sebastian Böttcher; Andreas Bühler; Raymonde Busch; Paula Cramer; Hartmut Döhner; Michael J Eckart; Barbara F Eichhorst; Thomas Elter; Dirk Winkler; Clemens-Martin Wendtner
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(26):3559-66.
2009: Eva Lengfelder; Claudia Haferlach; Susanne Saussele; Torsten Haferlach; Beate Schultheis; S Schnittger; Wolf-Dieter Ludwig; Peter Staib; Carlo Aul; A Grüneisen; W Kern; A Reichle; Hubert Serve; Wolfgang E Berdel; J Braess; K Spiekermann; Bernhard Wörmann; Maria Cristina Sauerland; Achim Heinecke; Wolfgang Hiddemann; Rüdiger Hehlmann; Thomas Büchner
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG.
Leukemia 2009;23(12):2248-58.
2009: Katharina Salome Minke; Peter Staib; Adriane Puetter; Iris Gehrke; Rajesh Kumar Gandhirajan; Axel Schlösser; Esther Katharina Schmitt; Michael Hallek; Karl-Anton Kreuzer
Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells.
European journal of haematology 2009;82(3):165-75.
2009: Thomas Büchner; Wolfgang E Berdel; Claudia Haferlach; Torsten Haferlach; Susanne Schnittger; Carsten Müller-Tidow; Jan Braess; Karsten Spiekermann; Joachim Kienast; Peter Staib; Andreas Grüneisen; Wolfgang Kern; Albrecht Reichle; Georg Maschmeyer; Carlo Aul; Eva Lengfelder; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang Hiddemann
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(1):61-9.
2007: Carmen Schweighofer; Gerd Fätkenheuer; Peter Staib; Michael Hallek; Marcel Reiser
Lyme disease in a patient with chronic lymphocytic leukemia mimics leukemic meningeosis.
Onkologie 2007;30(11):564-6.
2007: Andreas Draube; Jens M Chemnitz; Claudia Wickenhauser; Peter Staib; Michael Hallek; Karl-Anton Kreuzer
Cytomorphologic signs of severe pernicious anemia obscured in a patient with heterozygous hemoglobin Stanleyville II.
European journal of haematology 2007;79(4):360-2.
2007: A Koch; M Gaczkowski; G Sturton; Peter Staib; Timo Schinköthe; E Klein; Andrea Rubbert; K Bacon; Klaus Wassermann; Erland Erdmann
Modification of surface antigens in blood CD8+ T-lymphocytes in COPD: effects of smoking.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2007;29(1):42-50.
2007: Martin Schwonzen; Volker Diehl; Mario Dellanna; Peter Staib
Immunophenotyping of surface antigens in acute myeloid leukemia by flow cytometry after red blood cell lysis.
Leukemia research 2007;31(1):113-6.
2006: Annette Schmidt; Dennis Ladage; Timo Schinköthe; Ursula Klausmann; Christoph Ulrichs; Franz-Josef Klinz; Klara Brixius; Stefan Arnhold; Biren Desai; Uwe Mehlhorn; Robert H G Schwinger; Peter Staib; Klaus Addicks; Wilhelm Bloch
Basic fibroblast growth factor controls migration in human mesenchymal stem cells.
Stem cells (Dayton, Ohio) 2006;24(7):1750-8.
2006: Thomas Büchner; Wolfgang E Berdel; Claudia Schoch; Torsten Haferlach; Hubert Serve; Joachim Kienast; Susanne Schnittger; Wolfgang Kern; Joëlle Tchinda; Albrecht Reichle; Eva Lengfelder; Peter Staib; Wolf-Dieter Ludwig; Carlo Aul; Hartmut Eimermacher; Leopold Balleisen; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang Hiddemann
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2480-9.
2006: Peter Staib; Melanie Hoffmann; Timo Schinköthe
Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2006;44(1):28-31.
2005: Thomas Büchner; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Torsten Haferlach; Susanne Schnittger; Wolfgang Kern; Carlo Aul; Eva Lengfelder; Andrea Schumacher; Albrecht Reichle; Peter Staib; Leopold Balleisen; Hartmut Eimermacher; Andreas Grüneisen; Herbert Rasche; Maria Cristina Sauerland; Achim Heinecke; Rolf M Mesters; Hubert Serve; Joachim Kienast; Wolfgang Hiddemann
Treatment of older patients with AML.
Critical reviews in oncology/hematology 2005;56(2):247-59.
2005: Franz-Josef Klinz; Annette Schmidt; Timo Schinköthe; Stefan Arnhold; Biren Desai; Frank Popken; Klara Brixius; Robert H G Schwinger; Uwe Mehlhorn; Peter Staib; Klaus Addicks; Wilhelm Bloch
Phospho-eNOS Ser-114 in human mesenchymal stem cells: constitutive phosphorylation, nuclear localization and upregulation during mitosis.
European journal of cell biology 2005;84(10):809-18.
2005: Thomas Elter; Peter Borchmann; Holger Schulz; Marcel Reiser; Sven Trelle; Roland Schnell; Markus Jensen; Peter Staib; Timo Schinköthe; Hartmut Stützer; Juergen Rech; Martin Gramatzki; Walter Aulitzky; Ibrahim Hasan; Andreas Josting; Michael Hallek; Andreas Engert
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7024-31.
2005: Hans Michael Kvasnicka; Hans Michael Kvasnicka; Annette Schmitt-Graeff; Susanne Kriener; Knut Engels; Peter Staib; Esther Ollig; C Keller; S Fokkema; Martin Griesshammer; Cornelius F Waller; O G Ottmann; Martin-Leo Hansmann
Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients.
Histopathology 2005;46(5):540-50.
2005: Peter Staib; Elke Staltmeier; Katja Neurohr; Oliver A Cornely; Marcel Reiser; Timo Schinköthe
Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci.
British journal of haematology 2005;128(6):783-91.
2005: Thomas Buechner; Wolfgang E Berdel; Claudia Schoch; Torsten Haferlach; Hubert Serve; Susanne Schnittger; Wolfgang Kern; Joëlle Tchinda; Albrecht Reichle; Peter Staib; Wolf-Dieter Ludwig; Carlo Aul; Maria Cristina Sauerland; Achim Heinecke; Bernhard Woermann; Wolfgang Hiddemann
Treatment of AML in biological subgroups.
Hematology (Amsterdam, Netherlands) 2005;10 Suppl 1():281-85.
2005: Peter Staib; Jan Tiehen; Timo Strunk; Timo Schinköthe
Determination of caspase-3 activation fails to predict chemosensitivity in primary acute myeloid leukemia blasts.
BMC cancer 2005;5():60.
2004: Hans Michael Kvasnicka; Hans Michael Kvasnicka; Eva Varus; Susanne Kriener; Knut Engels; Peter Staib; Esther Ollig; Martin Griesshammer; Cornelius F Waller; H Pfeifer; Annette Schmitt-Gräff
[Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)].
Der Pathologe 2004;25(6):428-35.
2004: Hans Michael Kvasnicka; Hans Michael Kvasnicka; Annette Schmitt-Graeff; Susanne Kriener; Knut Engels; Peter Staib; Martin Griesshammer; Cornelius F Waller; O G Ottmann; M-L Hansmann
Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia.
Histology and histopathology 2004;19(4):1277-88.
2004: Hans Michael Kvasnicka; Hans Michael Kvasnicka; Eva Varus; Esther Ollig; Annette Schmitt-Graeff; Peter Staib; Martin Griesshammer
Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study.
Leukemia & lymphoma 2004;45(8):1627-31.
2004: Hans Michael Kvasnicka; Hans Michael Kvasnicka; Peter Staib; Annette Schmitt-Graeff; Martin Griesshammer; Jens Klose; Knut Engels; Susanne Kriener
Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy.
Blood 2004;103(9):3549-51.
2004: Martin R Weihrauch; Peter Staib; Bettina Seiberlich; Martin Hoffmann; Volker Diehl; Hans Tesch
Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Leukemia & lymphoma 2004;45(4):699-704.
2004: Hans Michael Kvasnicka; Hans Michael Kvasnicka; Peter Staib; Knut Engels; Susanne Kriener; Annette Schmitt-Graeff
[Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia].
Der Pathologe 2004;25(2):127-34.
2004: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Christa Fonatsch; Helmut Löffler; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; Leopold Balleisen; Andreas Grüneisen; Carlo Aul; Eva Lengfelder; Rüdiger Hehlmann; Wolfgang Kern; Hubert Serve; Rolf M Mesters; Hartmut Eimermacher; Norbert Frickhofen; Joachim Kienast; A Giagounidis; Maria Cristina Sauerland; Achim Heinecke
Subgroup specific therapy effects in AML: AMLCG data.
Annals of hematology 2004;83 Suppl 1():S100-1.
2003: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Christa Fonatsch; Helmut Löffler; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; Carlo Aul; Andreas Gruneisen; Eva Lengfelder; Norbert Frickhofen; Wolfgang Kern; Hubert Serve; Rolf M Mesters; Maria Cristina Sauerland; Achim Heinecke
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4496-504.
2003: Torsten Haferlach; Claudia Schoch; Helmut Löffler; Winfried Gassmann; Wolfgang Kern; Susanne Schnittger; Christa Fonatsch; Wolf-Dieter Ludwig; Christian Wuchter; Brigitte Schlegelberger; Peter Staib; Albrecht Reichle; Uschi Kubica; Hartmut Eimermacher; Leopold Balleisen; Andreas Grüneisen; Detlef Haase; Carlo Aul; Jochen Karow; Eva Lengfelder; Bernhard Wörmann; Achim Heinecke; Maria Cristina Sauerland; Thomas Büchner; Wolfgang Hiddemann
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):256-65.
2002: Jens M Chemnitz; Andreas Draube; Christof Scheid; Peter Staib; Armin Schulz; Volker Diehl; Dietmar Söhngen
Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab.
American journal of hematology 2002;71(2):105-8.
2002: Susanne Schnittger; Claudia Schoch; Martin Dugas; Wolfgang Kern; Peter Staib; Christian Wuchter; Helmut Löffler; Cristina Sauerland; Hubert Serve; Thomas Büchner; Torsten Haferlach; Wolfgang Hiddemann
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
Blood 2002;100(1):59-66.
2002: Barbara Krug; Hartmut Stützer; Ulrich Wolters; Cornelia Mauch; Peter Staib; Ulrich Töx; Hans Michael Steffen; Mathias Warm; S Ghafur; F Araba; Dirk J Beuckelmann; D P König; Markus Zähringer; Stefan Palm; Ekkehard von Pritzbuer; Matthias Schrappe
[Development of ultrasonography in a radiological university department from 1994 to 2001].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 2002;174(6):767-75.
2002: M Reiser; Andreas Josting; M Soltani; Peter Staib; B Salzberger; Volker Diehl; Andreas Engert
T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors.
Leukemia & lymphoma 2002;43(4):805-11.
2002: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Helmut Löffler; Torsten Haferlach; Andrea Schumacher; Peter Staib; Leopold Balleisen; Andreas Grüneisen; Herbert Rasche; Carlo Aul; Axel Heyll; Eva Lengfelder; Wolf-Dieter Ludwig; Georg Maschmeyer; Hartmut Eimermacher; Jochen Karow; Norbert Frickhofen; Wolf-Dietrich Hirschmann; Maria Cristina Sauerland
Acute myeloid leukemia: treatment over 60.
Reviews in clinical and experimental hematology 2002;6(1):46-59; discussion 86-7.
2001: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Helmut Löffler; Claudia Schoch; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; R Andreesen; Leopold Balleisen; Detlef Haase; Hartmut Eimermacher; Carlo Aul; Herbert Rasche; J Uhlig; Andreas Grüneisen; H E Reis; J Hartlapp; Wolf-Dietrich Hirschmann; H J Weh; H J Pielken; Winfried Gassmann; Maria Cristina Sauerland; Achim Heinecke
Remission induction therapy: the more intensive the better?
Cancer chemotherapy and pharmacology 2001;48 Suppl 1():S41-4.
2001: Peter Borchmann; Roland Schnell; R Knippertz; Jan Oliver Staak; Gabriella Camboni; A Bernareggi; Kai Hübel; Peter Staib; A Schulz; Volker Diehl; Andreas Engert
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(5):661-7.
2001: Oliver A Cornely; Jens M Chemnitz; Hans-Georg Brochhagen; Karin Lemmer; H Schütt; Dietmar Söhngen; Peter Staib; Claudia Wickenhauser; Volker Diehl; Kathrin Tintelnot
Disseminated Neocosmospora vasinfecta infection in a patient with acute nonlymphocytic leukemia.
Emerging infectious diseases 2001;7(1):149-52.
2001: Claudia Schoch; Torsten Haferlach; Detlef Haase; Christa Fonatsch; Helmut Löffler; Brigitte Schlegelberger; Peter Staib; Maria Cristina Sauerland; Achim Heinecke; Thomas Büchner; Wolfgang Hiddemann
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
British journal of haematology 2001;112(1):118-26.
2000: Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann; Helmut Löffler; Wolf-Dieter Ludwig; Claudia Schoch; Torsten Haferlach; Georg Maschmeyer; Peter Staib; Carlo Aul; G A Heyll; Andreas Grüneisen; Herbert Rasche; J H Eimermacher; Leopold Balleisen; H J Pielken; H E Reis; Frank Griesinger; Albrecht Reichle; Maria Cristina Sauerland; Achim Heinecke
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?
International journal of hematology 2000;72(3):285-9.
2000: Eva Lengfelder; Anja Reichert; Claudia Schoch; Detlef Haase; Torsten Haferlach; Helmut Löffler; Peter Staib; Axel Heyll; Wolfgang Seifarth; Susanne Saussele; Christa Fonatsch; Winfried Gassmann; Wolf-Dieter Ludwig; Andreas Hochhaus; D Beelen; Carlo Aul; Maria Cristina Sauerland; Achim Heinecke; Rüdiger Hehlmann; Bernhard Wörmann; Wolfgang Hiddemann; Thomas Büchner
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.
Leukemia 2000;14(8):1362-70.
1999: H T Steinmetz; A Schulz; Peter Staib; Christof Scheid; A Glasmacher; A Neufang; Jeremy Franklin; Hans Tesch; Volker Diehl; P Dias Wickramanayake
Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML.
Annals of hematology 1999;78(9):418-25.
1999: P A Horn; Hans Tesch; Peter Staib; D Kube; Volker Diehl; Dimitris Voliotis
Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells.
Blood 1999;93(4):1435-7.
1999: Kai Hübel; K Hegener; Roland Schnell; Georg Mansmann; F Oberhäuser; Peter Staib; Volker Diehl; Andreas Engert
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
Annals of hematology 1999;78(2):73-7.
1999: Peter Staib; Bernd Lathan; Timo Schinköthe; S Wiedenmann; B Pantke; T Dimski; Dimitris Voliotis; Volker Diehl
Prognosis in adult AML is precisely predicted by the DISC-assay using the chemosensitivity-index Ci.
Advances in experimental medicine and biology 1999;457():437-44.
1998: Peter Staib; Bernd Lathan; S Knöppel-Schwark; Hans Tesch; Dimitris Voliotis; H T Steinmetz; Martin Schwonzen; PD Wickramanayake; Volker Diehl
Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(2):221-3.